Neuroblastoma is the most common extra-cranial solid tumour in children. Over half of all high-risk cases are expected to succumb to the disease even after chemotherapy, surgery, and immunotherapy. Although the importance of MYCN amplification in this disease is indisputable, the mechanistic details remain enigmatic. Here, we present a multicellular model of neuroblastoma comprising a continuous automaton, discrete cell agents, and a centre-based mechanical model, as well as the simulation results we obtained with it. The continuous automaton represents the tumour microenvironment as a grid-like structure, where each voxel is associated with continuous variables such as the oxygen level therein. Each discrete cell agent is defined by several attributes, including its cell cycle position, mutations, gene expression pattern, and more with behaviours such as cell cycling and cell death being stochastically dependent on these attributes. The centre-based mechanical model represents the properties of these agents as physical objects, describing how they repel each other as soft spheres. By implementing a stochastic simulation algorithm on modern GPUs, we simulated the dynamics of over one million neuroblastoma cells over a period of months. Specifically, we set up 1200 heterogeneous tumours and tracked the MYCN-amplified clone's dynamics in each, revealed the conditions that favour its growth, and tested its responses to 5000 drug combinations. Our results are in agreement with those reported in the literature and add new insights into how the MYCN-amplified clone's reproductive advantage in a tumour, its gene expression profile, the tumour's other clones (with different mutations), and the tumour's microenvironment are inter-related. Based on the results, we formulated a hypothesis, which argues that there are two distinct populations of neuroblastoma cells in the tumour; the p53 protein is pro-survival in one and pro-apoptosis in the other. It follows that alternating between inhibiting MDM2 to restore p53 activity and inhibiting ARF to attenuate p53 activity is a promising, if unorthodox, therapeutic strategy. The multicellular model has the advantages of modularity, high resolution, and scalability, making it a potential foundation for creating digital twins of neuroblastoma patients. Author summary: Neuroblastoma is the most common extra-cranial solid tumour in children. Although very low–risk, low-risk, and intermediate-risk cases have good survival rates, most high-risk patients succumb to the disease or relapse despite modern therapies. Neuroblastoma biology is still full of unanswered questions and successful treatment is likely to require a personalised approach. Mathematical and computational modelling could contribute to a better understanding of its origin and nature, as well as the ongoing effort to advance patient-specific therapies, partly because of the potential for integration with other emerging technologies such as multi-omics, medical imaging, data mining, machine learning, and high-performance computing. During the PRIMAGE project, we built, calibrated, and validated, to the best of our knowledge, the first multicellular computational model of neuroblastoma. As we reported in an earlier paper, this was integrated into a multi-scale orchestrated computational framework. Here, we describe how we used the multicellular computational model as a standalone component, to gain new insights into neuroblastoma. Armed with it, we carried out large-scale computer simulations involving over a million independent cell agents in the most expensive case and 5000 hypothetical drug combinations. Our results confirm and add new insights into the non-linear dynamics spanning the intracellular, intercellular, and microenvironmental scales of neuroblastoma. They also indicate that an unconventional therapy targeting a frequently overlooked role of p53 (DNA repair) is promising. On the basis of these results, we believe that our model will be useful for the in silico medicine community. We hope that it will one day become the foundation of a virtual neuroblastoma. [ABSTRACT FROM AUTHOR]